Clinical trial • Phase III • Oncology|Other
Clinical trial in Cervical cancer|Cervical cancer stage I
Phase III trial for Cervical cancer|Cervical cancer stage I. 30 participants.
Overview
- Trial Therapeutic Area
- Oncology|Other
- Trial Disease
- Cervical cancer|Cervical cancer stage I
- Trial Stage
- Phase III
Key dates
- Initial CTIS Submission Date
- 07-11-2023
- First CTIS Authorization Date
- 22-02-2024
Trial design
Phase III trial across 1 site in Netherlands.
- Target Sample Size
- 30
- Trial Duration For Participant
- 547
Eligibility
Recruits 30 Vulnerable population selected: true; no further details on consent or assent handling available..
- Vulnerable Population
- Vulnerable population selected: true; no further details on consent or assent handling available.
Recruitment
- Planned Sample Size
- 30
- Recruitment Window Months
- 18
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 30
Netherlands
- Earliest CTIS Part Ii Submission Date
- 10-01-2024
- Latest Decision Or Authorization Date
- 22-02-2024
- Processing Time Days
- 43
- Number Of Sites
- 1
- Number Of Participants
- 30
Sites
- Site Name
- Amsterdam UMC
- Department Name
- Obstetrics & Gynaecology
- Contact Person Name
- Stijn Mom
- Contact Person Email
- c.h.mom@amsterdamumc.nl
- Number Of Participants
- 30
Sponsor
Primary sponsor
- Full Name
- Amsterdam UMC
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- Netherlands
Related trials
Other published trials that may interest you.
- Apalutamide for Prostate cancer
- TUB-040 for High-grade epithelial serous ovarian cancer | High-grade endometrioid epithelial ovarian cancer
- Abiraterone acetate for Metastatic castration-resistant prostate cancer (mCRPC)
- IOMEPROL for Thoracic neoplasm|Primary pulmonary malignancy|Pleural malignancy
- (S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-CYANO-4,4-DIFLUOROPYRROLIDIN-1-YL)-2-OXOETHYLCARBAMOYL)-QUINOLIN-6-YL)(METHYL)AMINO)-PROPYL)PIPERAZIN-1-YL)-2-OXOETHYL)-68GA-[1,4,7,10]-TETRAAZACYCLODODECANE-1,4,7-TRIYL)TRIACETATE for Gastric cancer|Gastric adenocarcinoma|Signet-ring cell adenocarcinoma